secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001193125-25-321663
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru reports FY2025 net loss $22.7M, cash $15.8M; enobosarm Phase 2b PLATEAU to start Q1'26
--------------------------------------------------------------------------------

- Net loss from continuing ops $15.7M ($1.07/sh) vs $35.3M ($2.61/sh) prior year; total net loss $22.7M ($1.55/sh).
- Post year-end public offering net proceeds ~$23.4M; cash as of Sep 30, 2025 was $15.8M vs $24.9M prior year.
- FDA confirmed enobosarm 3 mg acceptable; incremental weight loss of ≥5% placebo-corrected at 52 weeks acceptable primary endpoint for approval.
- Phase 2b QUALITY: enobosarm 3 mg preserved 100% lean mass, reduced physical function decline (≥10% stair climb power) from 44.8% to 17.6% with semaglutide.
- Phase 2b PLATEAU of enobosarm 3 mg + GLP-1 RA in 200 obesity patients starts Q1 2026; interim results Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/0001193125-25-321663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-321663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer